Mapp Biopharmaceutical

Researchers initiated a study on two potential Ebola treatments, remdesivir and MBP134, in Congo to address the worsening Bundibugyo virus outbreak, which has infected over 1,400 people and caused 438 deaths. The trial, led by the WHO and partners, aims to determine if the drugs improve survival rates and will enroll participants in eastern Congo, with possible expansion to safer regions.

Researchers in Congo began testing two potential Ebola treatments, remdesivir and MBP134, to address the worsening Bundibugyo virus outbreak, which has infected over 1,400 people and caused 438 deaths. The World Health Organization (WHO) is leading the trial, which aims to determine if these drugs improve survival rates in combination with standard care. The study involves collaboration with Congo’s INRB, Oxford University, and other international health groups.

Researchers in Congo have initiated a study to test two potential Ebola treatments, remdesivir and MBP134, amid a worsening outbreak caused by the Bundibugyo virus. The World Health Organization reported over 1,400 cases and 438 deaths, with the trial aiming to determine if the drugs improve survival rates. The study, conducted in collaboration with multiple international institutions, faces challenges due to violence in the region.

The US will supply an experimental Ebola drug, MBP134, to DR Congo for clinical trials. The WHO will also test Remdesivir, a COVID-19 treatment, on Ebola patients, as scientists race to develop vaccines for the new Bundibugyo strain. Disagreements over pathogen sharing have delayed lab testing for treatments and vaccines.